O'Connor Timothy P, Crystal Ronald G
Department of Genetic Medicine, Weill Medical College of Cornell University, 515 East 71st Street, S-1000, New York 10021, USA.
Nat Rev Genet. 2006 Apr;7(4):261-76. doi: 10.1038/nrg1829.
The treatment of the more than 1,800 known monogenic hereditary disorders will depend on the development of 'genetic medicines' - therapies that use the transfer of DNA and/or RNA to modify gene expression to correct or compensate for an abnormal phenotype. Strategies include the use of somatic stem cells, gene transfer, RNA modification and, in the future, embryonic stem cells. Despite the efficacy of these technologies in treating experimental models of hereditary disorders, applying them successfully in the clinic is a great challenge, which will only be overcome by expending considerable intellectual and economic resources, and by solving societal concerns about modifications of the human genetic repertoire.
治疗1800多种已知的单基因遗传性疾病将依赖于“基因药物”的研发——这类疗法通过转移DNA和/或RNA来修饰基因表达,以纠正或补偿异常表型。策略包括使用体干细胞、基因转移、RNA修饰,以及未来使用胚胎干细胞。尽管这些技术在遗传性疾病实验模型的治疗中有效,但要在临床上成功应用它们是一项巨大挑战,只有投入大量智力和经济资源,并解决社会对人类基因库修饰的担忧,才能克服这一挑战。